Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00981370 · ClinicalTrials.gov registry record · Phase 3
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
A Phase 3 study, sponsored by Children's Hospital Los Angeles.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT00981370: Clinical Trial Phase 3 study, sponsored by Children's Hospital Los Angeles.
NCT00981370 is a Phase 3 study that was terminated before completion, run by Children's Hospital Los Angeles. The registered enrollment target is 1 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00981370, a Phase 3 study, was terminated before completion, sponsored by Children's Hospital Los Angeles.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
Hypothesis: The investigators suspect that significant degrees of iron overload in subjects with SCD result in decreased red cell survival, abnormal endothelial function and markedly dysregulated autonomic function. Furthermore, the investigators anticipate that the magnitude of these effects is proportional not only to the magnitude of total body iron stores but also to the duration of exposure to the high iron levels in tissues. Primary objective To determine if red cell survival as assessed by 51Cr red cell survival analysis, hemoglobin level, reticulocyte count, lactic acid dehydrogenase, and plasma hemoglobin in sickle cell patients is related to the degree of iron overload. Secondary objective(s) 1. Determine if the magnitude of endothelial-dependant vasodilation is related to The degree of iron overload. 2. Determine if the degree of change in cardiac beat to beat variability in response to hypoxic exposure or to cold exposure ("cold-face-test") is related the magnitude of iron overload. The primary measure of iron overload will be MRI determination of liver iron concentration.
Interventions
- DRUG deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
Why NCT00981370 stopped before completion
NCT00981370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which deferasirox is the first listed.
NCT00981370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00981370 about?
NCT00981370 is a clinical study titled "Clinical Importance of Treating Iron Overload in Sickle Cell Disease". Hypothesis: The investigators suspect that significant degrees of iron overload in subjects with SCD result in decreased red cell survival, abnormal endothelial function and markedly dysregulated autonomic function. Furthermore, the investigators anticipate that the magnitude of these effects is pr...
What is the current status of trial NCT00981370?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2009-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00981370?
The interventions under investigation include: deferasirox (DRUG).
Who is sponsoring clinical trial NCT00981370?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00981370's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia